Nothing Special   »   [go: up one dir, main page]

CO2017001384A2 - Anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc épsilon - Google Patents

Anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc épsilon

Info

Publication number
CO2017001384A2
CO2017001384A2 CONC2017/0001384A CO2017001384A CO2017001384A2 CO 2017001384 A2 CO2017001384 A2 CO 2017001384A2 CO 2017001384 A CO2017001384 A CO 2017001384A CO 2017001384 A2 CO2017001384 A2 CO 2017001384A2
Authority
CO
Colombia
Prior art keywords
receptor
antibodies directed
epsilon
iib
gamma
Prior art date
Application number
CONC2017/0001384A
Other languages
English (en)
Inventor
Anna Carle
Carolin Direnberger
Peter Sondermann
Martina Mueller
Nicole Rieth
Thomas Pohl
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51355407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017001384(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Publication of CO2017001384A2 publication Critical patent/CO2017001384A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se divulgan en la presente moléculas de reconocimiento que se unen con un primer dominio de unión al receptor de Fc épsilon (FcεR) y con un segundo dominio de unión al receptor IIB de Fc gamma (FcRIIB), así como también usos para dichas moléculas de reconocimiento.
CONC2017/0001384A 2014-08-13 2017-02-10 Anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc épsilon CO2017001384A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14002825 2014-08-13
PCT/EP2015/068667 WO2016023985A1 (en) 2014-08-13 2015-08-13 Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor

Publications (1)

Publication Number Publication Date
CO2017001384A2 true CO2017001384A2 (es) 2017-05-10

Family

ID=51355407

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0001384A CO2017001384A2 (es) 2014-08-13 2017-02-10 Anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc épsilon

Country Status (19)

Country Link
US (1) US10730946B2 (es)
EP (1) EP3180358B1 (es)
JP (1) JP6808611B2 (es)
KR (1) KR102424169B1 (es)
CN (1) CN106795223B (es)
AR (1) AR101555A1 (es)
AU (1) AU2015303142B2 (es)
BR (1) BR112017002755B1 (es)
CA (1) CA2957850A1 (es)
CL (1) CL2017000360A1 (es)
CO (1) CO2017001384A2 (es)
EA (1) EA035269B1 (es)
ES (1) ES2802176T3 (es)
IL (1) IL250569B (es)
MX (1) MX2017001895A (es)
MY (1) MY180940A (es)
SG (1) SG11201701028SA (es)
TW (1) TWI713464B (es)
WO (1) WO2016023985A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
ES2802176T3 (es) 2014-08-13 2021-01-15 Suppremol Gmbh Nuevos anticuerpos dirigidos contra el receptor IIB de Fc gamma y el receptor de Fc épsilon
WO2018036947A1 (en) * 2016-08-22 2018-03-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inhibiting biological responses induced by a receptor that uses pi3k to signal in a cell
EP4041397A1 (en) * 2019-10-01 2022-08-17 Epsilogen Ltd Hybrid antibody
AU2021329742A1 (en) * 2020-08-21 2023-03-23 Fatiabgen Inc. Antibody fragment consisting of heavy chain and light chain constant regions in which gamma constant region (CΓ1) and epsilon constant region (CE2-4) are fused, and use thereof
CN113214392B (zh) * 2020-12-30 2022-07-01 中国人民解放军海军军医大学 抗水母毒素纳米抗体ky031、制备方法及用途
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254753C1 (en) * 2001-05-01 2008-09-18 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
PL1709073T3 (pl) * 2003-11-26 2012-01-31 Max Planck Gesellschaft Substancja wiążąca receptor IIb Fc ludzkiej IgG (FcγRIIb)
WO2005115452A2 (en) * 2004-04-16 2005-12-08 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
KR101247908B1 (ko) * 2004-09-02 2013-03-26 제넨테크, 인크. 항-ｆｃ-감마 ｒｉｉｂ 수용체 항체 및 그의 용도
KR102030531B1 (ko) 2011-05-21 2019-10-10 마크로제닉스, 인크. 탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
ES2802176T3 (es) 2014-08-13 2021-01-15 Suppremol Gmbh Nuevos anticuerpos dirigidos contra el receptor IIB de Fc gamma y el receptor de Fc épsilon

Also Published As

Publication number Publication date
KR20170041250A (ko) 2017-04-14
BR112017002755A2 (pt) 2017-12-19
CN106795223B (zh) 2021-05-04
JP6808611B2 (ja) 2021-01-06
ES2802176T3 (es) 2021-01-15
JP2017529832A (ja) 2017-10-12
AU2015303142A1 (en) 2017-03-02
US10730946B2 (en) 2020-08-04
AR101555A1 (es) 2016-12-28
EA035269B1 (ru) 2020-05-22
CN106795223A (zh) 2017-05-31
BR112017002755B1 (pt) 2023-12-26
IL250569A0 (en) 2017-03-30
MX2017001895A (es) 2017-08-28
AU2015303142B2 (en) 2020-08-06
EP3180358B1 (en) 2020-04-01
CA2957850A1 (en) 2016-02-18
KR102424169B1 (ko) 2022-07-25
IL250569B (en) 2021-05-31
EP3180358A1 (en) 2017-06-21
US20170226208A1 (en) 2017-08-10
MY180940A (en) 2020-12-14
SG11201701028SA (en) 2017-03-30
TWI713464B (zh) 2020-12-21
TW201629099A (zh) 2016-08-16
WO2016023985A1 (en) 2016-02-18
EA201790314A1 (ru) 2017-06-30
CL2017000360A1 (es) 2017-07-14

Similar Documents

Publication Publication Date Title
CO2017001384A2 (es) Anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc épsilon
BR112016022841A2 (pt) cadeia j modificada
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
BR112018008867A2 (pt) anticorpos que se ligam especificamente a pd-1 e seus usos
DOP2016000224A (es) Tratamientos combinados con anticuerpos anti-cd38
CL2017001361A1 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CR20170079A (es) Agentes de unión a cd123 y usos de estos
BR112017008945A2 (pt) Anticorpos anti-cs1 e conjugados fármaco- anticorpo
BR112018006471A2 (pt) compostos úteis como moduladores de trpm8
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
BR112014019331A2 (pt) anticorpos para cd47 e métodos de uso desses
BR112017027724A2 (pt) terapias de combinação para malignidades hematológicas com anticorpos anti-cd38 e inibidores de survivina
MX2017006233A (es) Celula.
BR112018002432A2 (pt) anticorpos de ligação à il-8 e usos dos mesmos
CL2015002742A1 (es) Moléculas de unión para bcma y cd3.
NI201700016A (es) Conjugados de fármacos con anticuerpos anti-cdh6
BR112016022727A2 (pt) ?imunorreceptores específicos de claudina-6 e epítopos de células t
EA201790173A1 (ru) Антитела, связывающие axl
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
CR20140440A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
BR112017013111A2 (pt) métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo